Fulcrum Therapeutics, Inc. (FULC)
12.99
+0.19
(+1.48%)
USD |
NASDAQ |
Dec 12, 16:00
12.99
0.00 (0.00%)
After-Hours: 17:41
Fulcrum Therapeutics Research and Development Expense (Quarterly): 14.00M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Agios Pharmaceuticals, Inc. | 85.42M |
| Biogen, Inc. | 369.60M |
| CorMedix, Inc. | 5.098M |
| Apellis Pharmaceuticals, Inc. | 68.19M |
| NovaBay Pharmaceuticals, Inc. | -- |